Here's a yet another seasonal illness, always traveling hand in hand with what we wrote about yesterday - the common cold and the flu. Children who have caught an unfortunate Respiratory synctial virus (which they most likely will do at least once every year, when aged 4 to 16) can...
Blog
Childhood Illnesses: RSV
Here's a yet another seasonal illness, always traveling hand in hand with what we wrote about yesterday - the common cold and the flu. Children who have caught an unfortunate Respiratory synctial virus (which they most likely will do at least once every year, when aged 4 to 16) can...
QSAM Biosciences Receives Rare Pediatric Disease Designation from FDA for CycloSam in the Treatment of Osteosarcoma
Austin, TX, Feb. 02, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases, today announces that the United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to QSAM’s clinical-stage drug candidate,...
QSAM Biosciences Appoints Adriann Sax to Board of Directors
Austin, TX, Jan. 25, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases, today announces the appointment of Adriann Sax to the QSAM Biosciences Board of Directors. Ms. Sax will serve on the Company’s Audit...
QSAM Biosciences Activates Clinical Sites and Opens Enrollment for its Phase 1 Clinical Trial of CycloSam® for the Treatment of Bone Cancer
Austin, TX, Dec. 01, 2021 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®), for the treatment of cancer and related diseases, today announces the activation of its first clinical trial site and the initiation of enrollment of patients into its Phase 1 clinical...